XFOR — X4 Pharmaceuticals, Inc
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2017-11-16.
Performance
Technicals
Others in Healthcare
Measured signals that fired on XFOR
| date | signal | measured base rate |
|---|---|---|
| 2026-08-07 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-30 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-06-26 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
| 2026-05-18 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-12 | Craig Adam R Executive Chairman | Open-market sale | 47.4K | 4.44 | 210.8K |
| 2026-08-12 | Volpone John President | Open-market sale | 24.6K | 4.44 | 109.2K |
| 2026-06-30 | KIRSKE DAVID Chief Financial Officer | Open-market sale | 8.5K | 4.26 | 36.4K |
| 2026-05-12 | KIRSKE DAVID Chief Financial Officer | Open-market sale | 17.0K | 4.29 | 72.8K |
| 2025-10-23 | Craig Adam R Executive Chairman | Open-market purchase | 86.2K | 2.90 | 250.0K |
| 2025-08-14 | KIRSKE DAVID Chief Financial Officer | Grant or award | 193.3K | 0.00 | 0 |
| 2025-08-14 | Volpone John President | Grant or award | 289.9K | 0.00 | 0 |
| 2025-08-14 | Craig Adam R Executive Chairman | Grant or award | 289.9K | 0.00 | 0 |
| 2025-06-09 | Bridger Gary Director | Grant or award | 1.5K | 0.00 | 0 |
| 2025-06-09 | Woods Keith Director | Grant or award | 1.5K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| MORGAN STANLEY | 39.1M | 9.5M |
| Empery Asset Management, LP | 36.9M | 8.9M |
| FMR LLC | 33.5M | 8.1M |
| Bain Capital Life Sciences Investors, LLC | 32.9M | 8.0M |
| Kalehua Capital Management LLC | 30.8M | 7.4M |
| PERCEPTIVE ADVISORS LLC | 27.8M | 6.7M |
| Saturn V Capital Management LP | 26.7M | 6.5M |
| Deep Track Capital, LP | 26.2M | 6.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.4M | 3.5M |
| BRAIDWELL LP | 13.5M | 3.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about XFOR
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →